Valeant Pharmaceuticals: SEC Subpoena, Arizona Targets Company and Jorn Resigns – ValueWalk Premium
Valeant Pharmaceuticals Ad Hoc Committee

Valeant Pharmaceuticals: SEC Subpoena, Arizona Targets Company and Jorn Resigns

Valeant Pharmaceuticals: SEC Subpoena, Arizona Targets Company and Jorn Resigns by TheSkeptic

If this week wasn't bad enough for Valeant, Deb Jorn, the Executive Vice President and Company Group Chairman resigned today from the company. Ms. Jorn was responsible for all major US product launches as well as the Dermatology and GI therapeutic areas. These two areas were Valeant's most important, representing HALF of Valeant's forecasted 2016 US revenues. Moreover . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

0